IPF Partners
VC Fund
Luxembourg, Luxembourg
IPF Partners is a alternative financing provider focused on the European healthcare sector. IPF invests directly in emerging, commercial-stage European pharma/biotech, medtech and diagnostics companies.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $108M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries IPF Partners invests in
Health CareMedical DeviceMedicalBiotechnologyHospital
Stages IPF Partners invests in
Debt FinancingPost-IPO DebtSeries CVenture - Series UnknownSeries B
Countries IPF Partners invests in
FranceFinlandIrelandUnited StatesUnited Kingdom
Round sizes
Series C $28M–$130MPost-IPO Debt $3.5M–$30MDebt Financing $1.8M–$32M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series C
- $28M–$130M
- Post-IPO Debt
- $3.5M–$30M
- Debt Financing
- $1.8M–$32M
Investment Focus
Industry
- Health Care 10 (50%)
- Medical Device 6 (30%)
- Medical 5 (25%)
- Biotechnology 5 (25%)
- Hospital 2 (10%)
Stage
- Debt Financing 6 (30%)
- Post-IPO Debt 4 (20%)
- Series C 2 (10%)
- Venture - Series Unknown 2 (10%)
- Series B 1 (5%)
Country
- France 4 (20%)
- Finland 2 (10%)
- Ireland 2 (10%)
- United States 2 (10%)
- United Kingdom 2 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Edouard Guillet
Partner
|
Partner | Total investments: 1 | Find email | |
Georges Ralli
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. | $3.5M / Post-IPO Debt / Mar 04, 2024 | ||
| Patient21 believes that the doctor-patient connection is the cornerstone to good healthcare and that it is their responsibility to remove any impediments to it. They think that the greatest healthcare necessitates cross-specialty collaboration and universal data access. Always with one purpose in mind: to help patients and physicians make betterdecisions.In comparison to today's linked world, healthcare appears to be trapped in the past. It continues to use the same analogue and isolated processes. Patient21 is on a quest to usher healthcare into the twenty-first century. They use data to help doctors give the most personalized treatments possible. And, with the help of their professional network, they are attempting to give a comprehensive perspective of their client's health. | $32M / Debt Financing / May 22, 2023 | ||
| Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.They believe that targeting cellular energyregulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC). | Post-IPO Debt / Aug 08, 2022 | ||
| Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. | $30M / Post-IPO Debt / Feb 28, 2022 | ||
| Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $130M / Series C / Sep 16, 2021 | ||
| Lumeon is a digital health company that has defined the market for Care Pathway Management (CPM). From scheduling and revenue management to clinical reporting and aftercare, by looking across the end-to end care pathway, Lumeon addresses the system, and not just the symptom, behind healthcare transformation. Lumeon's customers number amongEurope’s fastest growing and most innovative healthcare providers including BUPA, Nuffield Health, Alliance Medical, HCA, Optegra and Newmedica. It is headquartered in London employing over 90 people. | $30M / Series D / Aug 11, 2020 | ||
| Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $45.6M / Series B / Dec 12, 2019 | ||
| Lumeon is a digital health company that has defined the market for Care Pathway Management (CPM). From scheduling and revenue management to clinical reporting and aftercare, by looking across the end-to end care pathway, Lumeon addresses the system, and not just the symptom, behind healthcare transformation. Lumeon's customers number amongEurope’s fastest growing and most innovative healthcare providers including BUPA, Nuffield Health, Alliance Medical, HCA, Optegra and Newmedica. It is headquartered in London employing over 90 people. | $28M / Series C / Dec 04, 2018 | ||
| SpineGuard is a French innovative medical company dedicated to the deployment and adoption of DSG® (Dynamic Surgical Guidance), powerful radiation-free real time sensing technology platform that spans a broad spectrum of skeletal applications from bone drilling instruments to automated placement of bone implants. Uniquely positioned to change thegame in orthopedic robotic surgery. Devices, built with the DSG technology, give real-time audio and visual feedback to the surgeons to secure and streamline skeletal implant placement for the benefit of patients, surgeons, operating room staff and healthcare providers. The PediGuard probes are the only devices with built-in DSG capability to improve the accuracy of pedicle screw placement. The PediGuard probes are handheld tools used by spine surgeons to perform pilot holes in the vertebrae before pedicle screw placement. An electrical conductivity measurement sensor, located at the tip of the drilling instruments, alerts the surgeon in real time and without using X-Ray imaging, about changes in conductivity that occur at the transition between cancellous bone, cortical bone and soft tissues/ blood. These devices are used in surgeries for all kind of patients, from pediatric in deformity corrections to adult in degenerative diseases requiring internal fixation. The PediGuard devices are available in different diameters and shapes (straight, curved, cannulated and Threaded). Our new product, The DSG® Connect App, allows collection and visualization on a tab of the signal measured at the tip of DSG Connect devices during pedicle drilling. These medical devices have assisted spine surgeons in accurately placing pedicle screws in over 80,000 spinal procedures around the world. With mounting clinical evidence (16 major Peer-Reviewed publications) confirming its efficacy, PediGuard devices are becoming a compelling answer to the clinical needs associated with safe and accurate pedicle screw placement. | $7M / Post-IPO Debt / Sep 13, 2018 | ||
| Genesis Automation is a single source, full-service automated system solutions provider. It designs and builds high-precision assembly, test, and special process equipment for a wide range of industries. Genesis Automation was founded in 1999 and is based in Cork, Ireland. | $25.7M / Venture - Series Unknown / Jan 21, 2018 | ||
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
47,147 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
Medical Investors
20,530 investors
Medical Device Investors
12,078 investors
Health Care VC Funds
35,356 investors
Biotech VC Funds
20,362 investors
Biotechnology VC Funds
18,327 investors
Medical VC Funds
17,653 investors
FAQ
What does IPF Partners invest in?
IPF Partners invests primarily in Health Care, Medical Device and Medical startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 20 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is IPF Partners's check size?
IPF Partners typically joins rounds of $28M–$130M at Series C, $3.5M–$30M at Post-IPO Debt and $1.8M–$32M at Debt Financing. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds IPF Partners participates in.
How do I contact IPF Partners?
Public channels for IPF Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at IPF Partners?
The team at IPF Partners includes Edouard Guillet (Partner) and Georges Ralli (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
